© 2009 International Society of Nephrology

Kidney International (2009) 75, 868; doi:10.1038/ki.2008.334

Calcium channel blocker-induced chylous ascites in peritoneal dialysis

Yu-Tzu Tsao¹ and Wei-Liang Chen¹

¹Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Neihu, Taipei, Taiwan Correspondence: Yu-Tzu Tsao, Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Number 325, Section 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan. E-mail: tsaoyutzu@gmail.com



Figure 1 | Chylous peritoneal dialysis effluent.

A 41-year-old uremic woman was presented to the emergency department with a 2-day history of painless cloudy peritoneal effluent (Figure 1). She had been undergoing continuous ambulatory peritoneal dialysis for 2 weeks due to end-stage Chinese herbs nephropathy, using 2-l exchanges four times daily with standard 1.5% dextrose dialysate solution. On examination, physical findings were unremarkable except mild epigastric tenderness. Laboratory studies showed hemoglobin 9.6 g per 100 ml, leukocyte count $6.17 \times 10^3 / \mu l$, albumin 3.9 g per 100 ml, lactate dehydrogenase $110 \, \text{IU/l}$, and normal liver function and lipid profile. A serum-to-ascites albumin gradient was 0.8 g per 100 ml. Analyses of the turbid peritoneal effluent yielded elevated triglyceride concentration (251 mg per 100 ml) without evidence of microorganisms or cellular components,

suggestive of chylous ascites. On reviewing her current medications, she had been prescribed lercanidipine 10 mg once daily 3 days ago. After discontinuation of lercarnidipine, the dialysis effluent cleared within 24 h. Re-challenge with lercarnidipine provoked the same adverse reaction within 16 h. Dihydropyridine calcium channel blockers have been rarely associated with chylous ascites in peritoneal dialysis patients; the mechanism is unknown. Other reported etiologies of nontraumatic chylous effluent include abdominal neoplasm (lymphoma, solid cancers, and carcinoid tumors), cirrhosis of liver, infection (tuberculosis and filariasis), inflammation (radiation, sarcoidosis, retroperitoneal fibrosis, pancreatitis, and Whipple's disease), dilated cardiomyopathy, nephrotic syndrome, and congenital lymphatic abnormalities.